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26Introduction: Osteoporosis related risk factors such as BMD have been associated with cardiovascular endpoints
27in previous studies but there have been no studies of integrated risk using risk factor algorithms.
28Methods: A sample of 358 peri- and postmenopausal women, mean age 59.3 (range 45–74) years were studied.
29Each individual had bone mineral density (BMD) measurements by dual energy X-ray absorptiometry. Fracture
30risk was assessed using the WHO FRAX algorithm and cardiovascular disease (CVD) risk using the Framingham
31Risk Tool.
32Results: Women with higher 10 year risk of major osteoporotic had signiﬁcantly higher cardiovascular risk
33(4.634% vs 8.36%, p=0.001). In multiple regression analysis, 5-year CVD risk was signiﬁcantly associated with
34the 10-year risk of having major osteoporotic (β=0.095, p=0.001) and hip (β=0.055, p=0.001) fracture.
35Women with the highest CVD risk were 5.4 times more likely to have higher risk of major osteoporotic fracture.
36Conclusions: Fracture risk, determined by using a multiple risk factor algorithm such as FRAX, was positively
37associatedwith higher cardiovascular risk determined by using the FraminghamRisk Tool. Awareness regarding
38these concurrent risk factors needs to be raised so that appropriate risk reduction can be implemented.
39© 2012 Published by Elsevier Inc.
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44 Introduction
45 The existence of a possible link between bone and atherogenic
46 pathways has been recognized for some time. Inverse relationships
47 between bone mineral density (BMD) and calciﬁed atherosclerotic
48 plaque have been reported in a number of population-based studies of
49 postmenopausal women [1–5]. A number of studies have also focused
50 on the relationship between plasma lipids and BMD [6–8].
51 Although BMD has shown a strong association with fracture risk,
52 most fractures occur in subjects with T-scores above −2.5, the
53 threshold typically used to deﬁne osteoporosis, which means that
54 relying solely on BMDwill miss many patients at risk of fracture. Clin-
55 ical risk factors are also associated with an increased probability of
56 osteoporosis-associated fractures in postmenopausal women, and a
57 number of algorithms have integrated multiple clinical risk factors,
58 with or without BMD, to produce estimates of absolute risk of osteo-
59 porotic fracture.
60 This approach of integrating multiple clinical risk factors which may
61 be additive or synergistic has been well developed in the cardiovascular
62 ﬁeldwith a number of tools for estimating absolute risk of cardiovascular
63 disease (CVD) in clinical practice with good predictive ability [9–14].
64In the present study, we investigated the relationship between
65bone and cardiovascular pathways by calculating fracture risk using
66the FRAX [15–18] tool and comparing it to cardiovascular risk assessed
67by the Framingham Heart Risk tool [9,10] in a large population of peri
68and postmenopausal women.
69Methods
70Subjects
71Study subjects were female twins over 45 years, recruited as part of
72the Northern Sydney Twin Study. Information from this twin cohort has
73been published in detail previously [7,19–22]. In brief, the twins were
74recruited through the Australian National Health and Medical Research
75Council (NHMRC) Twin Registry and from local media campaigns.
76Twins were invited to participate in an investigation into the genetic
77and environmental determinants of various diseases including osteoar-
78thritis, cardiovascular disease, asthma, and osteoporosis. The hospital's
79Human Research Ethics Committee approved the study. After providing
80written informed consent, each twin was interviewed separately in
81accordance with a standard questionnaire to collect demographic,
82lifestyle and medical history data.
83Except for hormone therapy, twins who used medications or who
84had medical conditions that could interfere with bone metabolism
85were excluded from the analysis. Hormone therapy use was recorded
86and included as a covariate in the statistical analyses. Menopause,
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87 either natural or surgical, was deﬁned as self-reported 12-month
88 amenorrhoea [23] and years since menopause (YSM) were recorded.
89 No blood hormone levels were investigated. Incidents of myocardial
90 infarctions (MI), heart failure and stroke were documented.
91 Zygosity in same-sex twins was determined from the twins' self-
92 report using questions from a validated questionnaire [24]. DNA ﬁn-
93 gerprinting was used to determine zygosity in twin pairs in which
94 their zygosity was either unknown or disputed.
95 Clinical characteristics and laboratory measurements
96 Characteristics of study participants included age, height (m),weight
97 (kg), BMI (kg/m2), systolic and diastolic blood pressure, menopausal
98 status, hormone therapy and OCP use, physical activity, alcohol intake
99 and smoking history, prior low-trauma fracture history as an adult,
100 history of parental hip fracture, use of glucocorticoids, diagnosis of
101 rheumatoid arthritis and secondary osteoporosis.
102 Fasting blood samples used in this study were collected and kept
103 as aliquots at −80 °C until analysis. Fasting serum total cholesterol
104 (TC), high density lipoprotein (HDL), and triglycerides (TG) were
105 measured and low density lipoprotein (LDL) levels were calculated
106 using standard formula: LDL=TC−HDL−(TG/5). Aortic calciﬁca-
107 tion was assessed from lateral thoracolumbar X-rays as described
108 by Kauppila et al. [25].
109 Bone mineral density measurements
110 Lumbar spine (LS), total hip, forearm and whole body scans were
111 performed on a fan beam dual-energy X-ray absorptiometry (DEXA)
112 bone densitometer (QDR 4500W, Hologic, Waltham, MA USA) at base-
113 line and follow-up visits.Measurements of bonemineral density (BMD)
114 of lumbar spine (LSMBD), femoral neck (FNBMD), total hip (HTBMD),
115 forearm (FORBMD) and whole body (WBBMD) were obtained using
116 standard protocols as previously described [7,19–21]. The same densi-
117 tometer was used throughout the entire study. Performance of the
118 DEXA scanner has been monitored. Routine daily QC scans of the
119 Spine Phantom were performed and the coefﬁcient of variation for QC
120 BMD measures in our unit was 0.98%. In vivo reproducibility has been
121 estimated from duplicate scans (155 patients with repositioning be-
122 tween scans) as coefﬁcients of variation (CV) and intraclass correlation
123 (ICC) for BMDmeasures. CV and ICC for LS, total hip, femoral neck BMD
124 were 0.74/0.998; 1.23/0.994 and 1.27/0.994 correspondingly.
125 The FRAX tool and fracture risk
126 FRAX® is a risk-assessment tool [15–18] developed frompopulation-
127 based cohorts in Europe, North America, Asia, and Australia that calcu-
128 lates the 10-year probability of hip fracture and major osteoporosis-
129 related fracture (clinical spine, forearm, hip, or proximal humerus).
130 FRAX comprises 11 clinical variables (age, sex, weight and height [to
131 give body mass index (BMI)], previous fracture as an adult, parental
132 hip fracture, current cigarette smoking, current (or 3 months of past)
133 use of glucocorticoids, diagnosis of rheumatoid arthritis, consumption
134 of three or more units of alcohol daily, and secondary osteoporosis) as
135 well as BMD-derived T-scores at the femoral neck. The 10-year probabil-
136 ity risk ofmajor osteoporotic (OSFrR) or hip fracture (HipFrR)was deter-
137 mined using the FRAX® risk-assessment tool developed from Australian
138 population-based cohort. The FRAX® risk-assessment tool was used
139 with and without BMD.
140 Absolute cardiovascular disease risk assessment
141 The Framingham Risk Equation is a predictive equation derived
142 from the Framingham Heart Study, which started in 1948 and has
143 been operational for more than 60 years. It was developed for several
144 cardiovascular disease endpoints by Anderson and colleagues in 1991
145[9,10]. The Framingham Risk Equation demonstrates predictive ability
146that is equal or superior to other methods of calculating absolute CVD
147risk, and is therefore recommended for use in Australian primary
148care. It has been incorporated into the online Australian absolute cardio-
149vascular disease risk calculator that has been used in this study cohort to
150predict the risk of a cardiovascular event over the next 5 years [9,10,26].
151The calculator is designed for use in adults aged 45–74 years without
152existing CVD or not already known to be at increased risk of CVD, the lat-
153ter deﬁned as the following groups— diabetes and age>60 years; diabe-
154tes with microalbuminuria; moderate or severe chronic kidney disease;
155previous diagnosis of familial hypercholesterolaemia; systolic blood
156pressure≥180 mm Hg or diastolic blood pressure≥110 mm Hg; serum
157total cholesterol>7.5 mmol/L).
158Statistical methods
159All statistical analyses were performed using the IBM SPSS Statistics
160v19 (SPSS Inc., Chicago, IL). For comparison between groups of 10-year
161risk of having major osteoporotic fracture tertiles, ANOVA analysis
162for continuous variables and chi-square tests for categorical variables
163were performed. To study the association between 10-year risk of
164having major osteoporotic or hip fracture and 5-year CVD risk, multiple
165regression analysiswas performed. All risk scoreswere log-transformed
166for the analysis. Since both FRAX and the Framingham Risk Tool incor-
167porate age and BMI as risk factors, those were not added in multiple
168regression analyses. Regression models were adjusted for years since
169menopause (YSM) and HRT use. Results from crude and adjusted
170models were obtained. FRAX options with and without BMD were
171used to calculate 10-year major osteoporotic and hip fracture risks.
172These were log transformed and used as dependent variables in
173each regression model. Log 5-year CVD risk was entered into crude
174and adjusted models as an independent continuous variable to
175calculate regression coefﬁcients. Adjusted means for log 10-year
176major osteoporotic and hip fracture (with and without BMD) were
177obtained from fully ﬁtted regression models where 5-year CVD risk
178was entered as the independent factor (categorised). Other possible
179confounders include Menopausal status, HRT use and physical activ-
180ity, and these were accounted for in the regression models. Adjusted
181means for total aortic calciﬁcation (dependent) were derived from
182regression models where categories of 10-year OSFrR tertiles were
183entered as independent factors and YSM, HRT use and physical activity
184as covariates.
185Results
186We studied 480 healthy twin volunteers (230 pairs) in 2010 (96
187monozygotic (MZ) and 134 dizygotic (DZ) pairs). For this study we
188randomly excluded one member of each MZ twin pair (n=96) and
189subjects who were not suitable for calculating absolute CVD risk, such
190as individuals over 74 years of age (n=6). There were 7 incidences of
191MI, 5 — heart failure, 8 — stroke reported in this study cohort. These
192subjects were also excluded.
193There were 358 women with a mean age of 59.3 (range 45–74)
194included in this analysis.
195Main characteristics of the participants stratiﬁed by 10-year OSFrR
196tertiles are presented in Table 1.
197Estimations of 10-year probability risk of having major osteoporotic
198or hip fracture were slightly higher using the FRAX tool without BMD
199included in the equation.
200As expected, women in the highest tertile of FRAX 10-year OSFrR
201were older and had signiﬁcantly lower BMD measures at all skeletal
202sites.
203These women also had higher total aortic calciﬁcation score
204(4.41±4.86 compared to 2.18±3.57 in the lowest tertile).
205As the cohort of this study was relatively young and healthy volun-
206teers, the average 10-year probability risks of major osteoporotic or hip
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207 fracture were relatively low at 4.17% (0.7–24) and 0.92% (0–15), respec-
208 tively and mean 5-year CVD risk was also modest at 6.68% (0–38).
209 Based on the Australian CVD risk guidelines, we categorised the 5-year
210 CVD risk as very low (b5%, n=191), low (5–9.9%, n=115) andmoderate
211 to high (>10% n=52) [27]. Moderate (10–14.9%, n=26) and high (>15,
212 N=26)CVD risk groupswere combined due to small numbers of individ-
213 uals in these two groups. The prevalence of women with >10% 5-year
214 CVD risk was higher in the highest tertile of 10-year probability of OSFrR.
215 There were 72 self-reported incidents of low-trauma fracture,
216 with 40 (33.6%) of these fractures present in the highest tertile of
217 10-year OSFrR women.
218 There was a signiﬁcant correlation between FRAX assessed 10-year
219 probability risk of having major osteoporotic or hip fracture (with or
220 without BMD) and 5-year CVD risk. Coefﬁcients of nonparametric
221 Spearman correlations are presented in Table 2.
222 Parameter estimates of the multiple regression models are presented
223 in Table 3. We found that 5-year CVD risk was signiﬁcantly associated
224 with the 10-year risk of having major osteoporotic (β=0.150, p=
225 0.001) and hip (β=0.076, p=0.001) fracture. These results were
226 similar when 10-year OSFrR and HipFrR were estimated by FRAX
227 no BMD option. After adjustment for other possible confounders
228 including YSM;HRT use and physical activity, the association remained
229 statistically signiﬁcant.
230 Adjusted means of 10-year probability of OSFrR and HipFrR across
231 categories of 5-year CVD risk are presented in Fig. 1. After adjustment
232 for YSM, BMI, history of smoking, alcohol intake, HRT use and physical
233activity, mean 10-year risks of having a hip fracture were 0.49±0.14;
2341.04±0.18 and 1.23±0.25 across b5%, 5–10% and≥10% categories of
2355-year CVD risk, respectively (pb0.05). Adjusted means of log10-year
236risks of having major osteoporotic fracture were 2.88±0.27; 4.48±
2370.35 and 4.42±0.49 across categories of 5-year CVD risk, respectively
238(pb0.05).
239Adjustedmeans of total scores of aortic calciﬁcations across tertiles
240of 10-year OSFrR are presented in Fig. 2 (models adjusted for YSM,
241HRT use and physical activity). Women in the highest tertile of
24210-year OSFrR had signiﬁcantly higher scores of aortic calciﬁcation
243compared to the women in lower tertiles (ACa scores: 4.6 vs 2.1 and
2442.4 from high to low tertile of 10-year OSFrR, respectively, pb0.001).
245Odds Ratios (OR) and relative risk (RR) for prevalent higher 10-year
246probability risk of having major osteoporotic or hip fracture per higher
Table 1t1:1
t1:2 Characteristics of the studyQ2 cohort stratiﬁed by tertiles of FRAX assessed 10-year probability risk of having major osteoporotic fracture (with BMD). Data are mean±SD, unless spec-
t1:3 iﬁed otherwise.
t1:4 Tertiles of FRAX assessed 10-year probability risk of having major osteoporotic fracture (with BMD) P
t1:5 Total
(N=358)
1
N=119
2
N=120
3
N=119
t1:6 Mean±SD Mean±SD Mean±SD Mean±SD
t1:7 10-year major OS Fr risk (with BMD) 4.17±3.49 1.45±0.42 3.14±0.67 7.99±3.69 0.000
t1:8 10-year major OS Fr risk (without BMD) 5.42±4.77 1.84±0.75 4.04±1.51 9.98±5.45 0.000
t1:9 10-year hip Fr risk (with BMD) 0.92±1.70 0.11±0.11 0.39±0.27 2.3±2.43 0.000
t1:10 10-year hip Fr risk (without BMD) 1.77±1.67 0.29±0.23 0.96±0.59 3.90±4.13 0.000
t1:11 Age (years) 60.56±7.89 53.93±5.33 60.58±4.89 67.17±7.06 0.000
t1:12 BMI (kg/m2) 26.87±4.91 27.01±5.15 27.37±4.74 26.17±4.79 0.148
t1:13 Bone mineral density (g/cm2)
t1:14 Lumbar spine 0.951±0.158 1.028±0.157 0.954±0.146 0.871±0.131 0.000
t1:15 Femoral neck 0.751±0.120 0.825±0.121 0.754±0.094 0.672±0.092 0.000
t1:16 Hip total 0.896±0.125 0.971±0.119 0.896±0.107 0.823±0.101 0.000
t1:17 Forearm total 0.522±0.057 0.557±0.044 0.525±0.049 0.484±0.054 0.000
t1:18 Whole body total 1.088±0.116 1.158±0.114 1.082±0.092 1.023±0.100 0.000
t1:19 Aortic calciﬁcation score 3.20±4.21 2.18±3.57 2.03±3.02 4.41±4.86 0.032
t1:20 Total cholesterol (mmol/L) 5.44±0.98 5.57±0.91 5.45±0.94 5.30±1.06 0.297
t1:21 HDLC (mmol/L) 1.45±0.39 1.49±0.36 1.42±0.39 1.43±0.41 0.734
t1:22 5-year CVD risk 6.68±8.42 4.64±7.23 7.03±9.24 8.36±8.25 0.000
t1:23 5-year CVD risk (N (%)) 0.000
t1:24 b5% 191 (53.3%) 88 (73.9%) 65 (54.2%) 38 (31.9%)
t1:25 5–14.99% 115 (32.1%) 21 (17.6%) 41 (34.2%) 53 (44.5%)
t1:26 ≥15% 52 (14.5%) 10 (8.4%) 14 (11.7%) 28 (23.5)
t1:27 Any fractures 72 (20.1%) 5 (4.2%) 27 (22.5%) 40 (33.6%) 0.000
t1:28
t1:29 Lifestyle characteristics
t1:30 Smoking history (N (%)) 0.942
t1:31 Never 224 (62.6%) 75 (63.0%) 72 (60.0%) 77 (64.7%)
t1:32 Current 42 (11.7%) 15 (12.6%) 15 (12.5%) 12 (10.1%)
t1:33 Ex-smoker 92 (25.7%) 29 (24.4%) 33 (27.5%) 30 (25.2%)
t1:34 Alcohol intake (N (%)) 0.221
t1:35 ≤1 drink per week 143 (39.9%) 40 (33.6%) 49 (40.8%) 54 (45.4%)
t1:36 2–14 drinks per week 208 (58.1%) 77 (64.7%) 69 (57.5%) 62 (52.1%)
t1:37 ≥14 drinks per week 7 (1.9%) 2 (1.6%) 2 (1.7%) 3 (2.5%)
t1:38 Physical activity (N (%)) 0.811
t1:39 None 19 (5.4%) 6 (5.0%) 8 (4.2%) 5 (4.2%)
t1:40 b30 min per day 165 (46.1%) 55 (46.2%) 51 (42.5%) 59 (49.6%)
t1:41 ≥30 min per day 174 (48.6%) 58 (48.3%) 61 (50.8%) 55 (46.2%)
Table 2 t2:1
t2:2Nonparametric Spearman correlations between 5-year CVD risk and FRAX assessed
t2:310-year probability risk of having major osteoporotic or hip fracture (with or without
t2:4BMD).
t2:510-year major osteoporotic
fracture risk
With BMD 0.427⁎⁎⁎
t2:6Without BMD 0.418⁎⁎⁎
t2:710-year hip fracture risk With BMD 0.398⁎⁎⁎
t2:8Without BMD 0.440⁎⁎⁎
⁎⁎⁎ pb0.001. t2:9
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247 5-year CVD are presented in Table 4Q3 . Women with the highest CVD risk
248 were 5.4 (95% CI 2.1–13.5) times more likely to have higher risk of
249 major osteoporotic fracture and 3.0 (95%CI 1.4–6.4) times more likely
250 to have higher hip fracture risk than women with lower CVD risk
251 (pb0.001).
252Discussion
253A number of previous studies have examined the relationship be-
254tween bone and cardiovascular risk, mostly using single endpoints
255such as BMD and vascular calciﬁcation at various sites as reviewed
256by Anagnostis et al. [28]. BMD has been linked to aortic calciﬁcation
257and mortality from cardiovascular disease in these studies. We have
258previously reported that increased FRAX scores were associated
259with cardiovascular disease in a population of women in primary
260care [29]; however cardiovascular disease cases were self-reported
261in that study. The present study appears to be the ﬁrst study to exam-
262ine the association between integrated fracture risk and an integrated
263cardiovascular risk determined from multiple risk factors. We found
264that women with high fracture risk higher cardiovascular risk. Aortic
265calciﬁcation score was associated with 10-year OSFrR independently
266from YSM, HRT use and physical activity. Although both cardiovascular
267risk and fracture risk are age-dependent, this relationship was not
268explained by age alone.
269Our observation that fracture risk was positively associated with
270cardiovascular risk in the multiple regression analysis concurs with
271previous studies of single risk factors such as BMD or aortic calciﬁca-
272tion [28]. More recently Wang et al. [5] reported that BMD in the
273femur and total body but not the lumbar spine were decreased signif-
274icantly in women with abdominal aortic calciﬁcation, however after
Table 3t3:1
t3:2 Regression coefﬁcients of the association between 5-year CVD risk and FRAX assessed
t3:3 10-year probability risk of having major osteoporotic or hip fracture (with or without
t3:4 BMD).
t3:5 Regression models
t3:6 Model I (crude) Model 2⁎ (adjusted)
t3:7 10-year major osteoporotic
fracture risk
With BMD 0.150⁎⁎⁎ 0.095⁎⁎
t3:8 Without BMD 0.165⁎⁎⁎ 0.101⁎⁎
t3:9 10-year hip fracture risk With BMD 0.076⁎⁎⁎ 0.055⁎⁎
t3:10 Without BMD 0.099⁎⁎ 0.064⁎
t3:11 Dependent: log transformed10-year probability risk of having major osteoporotic or
t3:12 hip fracture with and without BMD. Independent: Log 5-year CVD risk.
t3:13 Model 1: not adjusted.
t3:14 Model 2: adjusted for YSM; HRT use and physical activity.
⁎⁎⁎ pb0.001.t3:15
⁎⁎ pb0.01.t3:16
⁎ pb0.05.t3:17
Fig. 1. Adjusted means* of FRAX 10-year probability risk of having hip or major osteoporotic fracture (with and without BMD) across categories of 5-year CVD risk. * Means adjusted
for menopausal status, HRT use and physical activity.
4 J. Makovey et al. / Bone xxx (2012) xxx–xxx
Please cite this article as: Makovey J, et al, High osteoporotic fracture risk and CVD risk co-exist in postmenopausal women, Bone (2012),
http://dx.doi.org/10.1016/j.bone.2012.09.025
U
N
C
O
R
R
E
C
TE
D
 P
R
O
O
F
275 adjustment for age, aortic calciﬁcation was not related to BMD at any
276 site. Divers et al. [30] recently examined the relationship between
277 calciﬁed atherosclerotic plaque and BMD in African-Americans. They
278 observed signiﬁcant inverse relationships between BMD and calciﬁed
279 plaque independent of conventional cardiovascular risk factors. How-
280 ever their population all suffered from type II diabetes unlike our
281 healthy cohort. A number of studies have linked vascular calciﬁcation
282 to fracture risk, mainly hip fractures, [31–35], but integrated fracture
283 risk was not assessed in these studies.
284 A number of studies have also focused on the relationship be-
285 tween plasma lipids and BMD. Early postmenopausal women with
286 an atherogenic lipid proﬁle have been reported to have lower lumbar
287 and femoral neck BMD and had an increased risk of osteopaenia than
288 those with a normal lipid proﬁle [6], suggesting that hyperlipidaemia
289 may be associated with osteoporosis. An inverse relationship has been
290 found between lumbar spine BMD and total cholesterol in postmeno-
291 pausal women and HDL cholesterol in premenopausal women [7]. In
292 a longitudinal study in postmenopausal women aged 50–75 years,
293 thosewith the largest increases in serum cholesterol showed the greatest
294 decreases in spine BMD independently of change in the bodymass index
295 [8]. More recently Buizert et al. reported no association between total
296 cholesterol and broadband ultrasound attenuation in the calcaneus but
297 higher levels of HDL cholesterol were associated with lower broadband
298 ultrasound attenuation in the calcaneus [36] suggesting HDL cholesterol
299 levels do not explain the association between osteoporosis assessed by
300 QUS and CVD.
301 Our study has some strengths and limitations. Our population were
302 healthy volunteers who had not previously been assessed for dual car-
303 diovascular and fracture risk. However the healthy nature of our study
304 cohort meant that incident fractures and cardiovascular events were
305 very low and there was insufﬁcient power to analyse these events as
306 separate outcomes. Both cardiovascular risk and fracture risk include
307 age in their equations. The resulting limitations to statistical analyses
308 could not be entirely overcome.
309 In conclusion we found that fracture risk, determined using a mul-
310 tiple risk factor algorithm such as FRAX, was positively associated
311 with higher cardiovascular risk, determined using the Framingham
312Risk assessment tool. The relationship between bone health and
313cardiovascular risk factors needs further investigation. Awareness
314regarding these concurrent risk factors needs to be raised so that
315appropriate risk reduction for modiﬁable factors can be instituted.
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